Back to Search
Start Over
Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: a phase II study from the North American Marrow Transplant Group.
- Source :
-
Leukemia & lymphoma [Leuk Lymphoma] 1999 Sep; Vol. 35 (1-2), pp. 91-8. - Publication Year :
- 1999
-
Abstract
- To determine the long-term results of high-dose chemotherapy and stem cell support in relapsed or primary refractory Hodgkin disease patients. One hundred and thirty-one patients with relapsed or primary refractory Hodgkin's disease were treated with a dose-intensive therapy protocol consisting of etoposide (2400 mg/m2 continuous intravenous infusion) cyclophosphamide (7200 mg/m2 intravenously), and carmustine (300-600 mg/m2 intravenously) CBVi. All patients had previously failed conventional chemoradiotherapy. Severe toxicities were related to infectious, hepatic, and pulmonary complications. Fatal, regimen-related toxicity was 19%; liver and lung dysfunction, as well as infection, were the most frequent problems. Ninety-one (69%) of the patients achieved a complete response (CR) (95% CI = 59% to 75%) after CBVi and autologous stem cell infusion. With a median follow-up of 5.1 years (range 3.0 to 9.5 years), overall and event-free survival are 44% (95% CI = 33% to 47%) and 38% (95% CI = 28% to 46%) respectively. While univariate analysis did not reveal a statistically significant variable to predict a better response, responsiveness to therapy demonstrated a trend. We conclude that CBVi is an effective therapy for relapsed or refractory Hodgkin's disease, producing long-term, durable remissions.
- Subjects :
- Adolescent
Adult
Antineoplastic Combined Chemotherapy Protocols adverse effects
Carmustine administration & dosage
Combined Modality Therapy
Cyclophosphamide administration & dosage
Dose-Response Relationship, Drug
Etoposide administration & dosage
Humans
Infusions, Intravenous
Middle Aged
North America
Recurrence
Transplantation, Autologous
Treatment Outcome
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Hematopoietic Stem Cell Transplantation
Hodgkin Disease therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1042-8194
- Volume :
- 35
- Issue :
- 1-2
- Database :
- MEDLINE
- Journal :
- Leukemia & lymphoma
- Publication Type :
- Academic Journal
- Accession number :
- 10512166
- Full Text :
- https://doi.org/10.3109/10428199909145708